Candidate Clinical Correlate of Prognostic Outcome for Tuberculosis Study

What this Trial Is About

Researchers are investigating new ways to predict the risk of tuberculosis (TB) coming back in people who have already been treated for drug-susceptible pulmonary TB. This study is part of a larger effort called the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) and focuses on finding better biomarkers—measurable indicators in sputum or blood—that can forecast TB recurrence more accurately than current methods. These improved markers are important to help develop and test shorter and more effective TB treatment plans. The study evaluates two main diagnostic tests: the RS ratio, a non-culture sputum assay that measures active bacterial RNA synthesis to indicate ongoing TB activity, and blood-based immune response assays that assess the body's reaction to the bacteria. Participants are patients who have finished the standard 6-month HRZE treatment regimen for drug-susceptible TB. The study does not involve experimental treatments but rather observes these diagnostic tests to see how well they predict TB returning. Participants will be followed for one year, during which researchers will monitor for recurrent TB and assess how accurately the new biomarkers can predict this outcome. The study involves collecting sputum and blood samples to perform these tests and will track clinical outcomes to improve future TB treatment trials. The total duration for each participant's involvement is about one year, focusing on safety and effectiveness of these markers in routine healthcare settings.

Candidate Clinical Correlate of Prognostic Outcome for TB Study